Literature DB >> 8517702

Serum protein-binding characteristics of vancomycin.

H Sun1, E G Maderazo, A R Krusell.   

Abstract

A synthesis of studies of serum protein binding of vancomycin and its reported abnormal binding in serum with very high concentrations of immunoglobulin A (IgA) suggests that this antibiotic may be bound to more than one serum protein. Using an ultrafiltration method for separating free from bound drug and high-performance liquid chromatography to measure drug concentration, we studied the binding characteristics of vancomycin for alpha-1 acid glycoprotein, IgG, IgM, IgA, and albumin. The results showed that vancomycin does not bind to alpha-1 acid glycoprotein, IgG, or IgM. Major binding to albumin and IgA occurs, and total drug binding to serum proteins can be fully explained by binding to these two proteins. We calculated an N (number of binding sites per molecule) of 1.3 +/- 0.4 and a K (association constant) of 3.3 x 10(5) +/- 6.3 x 10(4) M-1 (NK = 4.3 x 10(5) M-1) for binding to IgA, whereas the corresponding NK value for albumin was only 527.5 M-1, indicating that vancomycin preferentially binds to IgA. Very high concentrations of IgA in serum (i.e., grams per deciliter), such as in patients with IgA myeloma, may result in the paradox of high (total) concentrations of vancomycin in serum that may be clinically ineffective.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8517702      PMCID: PMC187916          DOI: 10.1128/AAC.37.5.1132

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  A statistical method for the estimation of binding parameters in a complex system.

Authors:  R L Priore; H E Rosenthal
Journal:  Anal Biochem       Date:  1976-01       Impact factor: 3.365

2.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Ultrafiltration is theoretically equivalent to equilibrium dialysis but much simpler to carry out.

Authors:  J A Sophianopoulos; S J Durham; A J Sophianopoulos; H L Ragsdale; W P Cropper
Journal:  Arch Biochem Biophys       Date:  1978-04-15       Impact factor: 4.013

4.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

5.  Pharmacokinetics of vancomycin in patients with various degrees of renal function.

Authors:  G R Matzke; R W McGory; C E Halstenson; W F Keane
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

6.  Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.

Authors:  J C Rotschafer; K Crossley; D E Zaske; K Mead; R J Sawchuk; L D Solem
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

7.  Vancomycin quantitation by high-performance liquid chromatography in human serum.

Authors:  J B McClain; R Bongiovanni; S Brown
Journal:  J Chromatogr       Date:  1982-09-10

8.  Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis.

Authors:  D D Lindholm; J S Murray
Journal:  N Engl J Med       Date:  1966-05-12       Impact factor: 91.245

9.  Single-dose kinetics of intravenous vancomycin.

Authors:  D J Krogstad; R C Moellering; D J Greenblatt
Journal:  J Clin Pharmacol       Date:  1980-04       Impact factor: 3.126

10.  Vancomycin disposition: the importance of age.

Authors:  N R Cutler; P K Narang; L J Lesko; M Ninos; M Power
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

View more
  17 in total

1.  PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin.

Authors:  Krishna Muppidi; Jeffrey Wang; Guru Betageri; Andrew S Pumerantz
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

2.  Extracellular DNA impedes the transport of vancomycin in Staphylococcus epidermidis biofilms preexposed to subinhibitory concentrations of vancomycin.

Authors:  Natalya Doroshenko; Boo Shan Tseng; Robert P Howlin; Jill Deacon; Julian A Wharton; Philipp J Thurner; Brendan F Gilmore; Matthew R Parsek; Paul Stoodley
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

3.  Prospective Cohort Study of the Tolerability of Prosthetic Joint Infection Empirical Antimicrobial Therapy.

Authors:  Claire Triffault-Fillit; Florent Valour; Ronan Guillo; Michel Tod; Sylvain Goutelle; Sébastien Lustig; Michel-Henry Fessy; Christian Chidiac; Tristan Ferry
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

4.  Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.

Authors:  Jill M Butterfield; Nimish Patel; Manjunath P Pai; Thomas G Rosano; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

5.  Surface-stress sensors for rapid and ultrasensitive detection of active free drugs in human serum.

Authors:  Joseph W Ndieyira; Natascha Kappeler; Stephen Logan; Matthew A Cooper; Chris Abell; Rachel A McKendry; Gabriel Aeppli
Journal:  Nat Nanotechnol       Date:  2014-03-02       Impact factor: 39.213

6.  Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

Authors:  Keso Skhirtladze; Doris Hutschala; Tatjana Fleck; Florian Thalhammer; Marek Ehrlich; Thomas Vukovich; Markus Müller; Edda M Tschernko
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings.

Authors:  Wei Zhao; Florentia Kaguelidou; Valérie Biran; Daolun Zhang; Karel Allegaert; Edmund V Capparelli; Nick Holford; Toshimi Kimura; Yoke-Lin Lo; José-Esteban Peris; Alison Thomson; John N van den Anker; May Fakhoury; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

Review 8.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

9.  Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.

Authors:  Christian Radke; Dagmar Horn; Christian Lanckohr; Björn Ellger; Michaela Meyer; Thomas Eissing; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2017-07       Impact factor: 6.447

Review 10.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.